PDE5A and type 2 diabetes mellitus: Similarly, other possible confounders, including the prevalence of comorbidities (type 2 Diabetes Mellitus, hypertension, cardiovascular diseases), the use of glucose- and lipid-lowering drugs and of PDE5 inhibitors did not show a significant difference between the three groups.